JP2022538338A - リルピビリンを用いて小児患者におけるｈｉｖを治療する方法 - Google Patents

リルピビリンを用いて小児患者におけるｈｉｖを治療する方法 Download PDF

Info

Publication number
JP2022538338A
JP2022538338A JP2021577856A JP2021577856A JP2022538338A JP 2022538338 A JP2022538338 A JP 2022538338A JP 2021577856 A JP2021577856 A JP 2021577856A JP 2021577856 A JP2021577856 A JP 2021577856A JP 2022538338 A JP2022538338 A JP 2022538338A
Authority
JP
Japan
Prior art keywords
rilpivirine
pharmaceutically acceptable
acceptable salt
subject
reverse transcriptase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021577856A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538338A5 (enExample
Inventor
クローウェウス，ヘルタ
ヴァンヴェゲル，シモン
エイゲン，ヴェーレ ヴァン
Original Assignee
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー filed Critical ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Publication of JP2022538338A publication Critical patent/JP2022538338A/ja
Publication of JP2022538338A5 publication Critical patent/JP2022538338A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021577856A 2019-07-03 2020-07-02 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法 Withdrawn JP2022538338A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03
US62/870,413 2019-07-03
PCT/EP2020/068734 WO2021001508A1 (en) 2019-07-03 2020-07-02 Methods of treating hiv in pediatric patients with rilpivirine

Publications (2)

Publication Number Publication Date
JP2022538338A true JP2022538338A (ja) 2022-09-01
JP2022538338A5 JP2022538338A5 (enExample) 2023-07-11

Family

ID=71579550

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577856A Withdrawn JP2022538338A (ja) 2019-07-03 2020-07-02 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
JP2021577871A Withdrawn JP2022538449A (ja) 2019-07-03 2020-07-03 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021577871A Withdrawn JP2022538449A (ja) 2019-07-03 2020-07-03 リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Country Status (14)

Country Link
US (3) US20210000823A1 (enExample)
EP (2) EP3993799A1 (enExample)
JP (2) JP2022538338A (enExample)
KR (2) KR20220028049A (enExample)
CN (2) CN114126655A (enExample)
AU (2) AU2020300818A1 (enExample)
BR (2) BR112021026916A2 (enExample)
CA (1) CA3144307A1 (enExample)
IL (1) IL289457A (enExample)
JO (1) JOP20210347A1 (enExample)
MA (2) MA56449A (enExample)
MX (2) MX2022000060A (enExample)
PH (1) PH12021553288A1 (enExample)
WO (2) WO2021001508A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538449A (ja) * 2019-07-03 2022-09-02 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519325A (ja) * 2015-06-30 2018-07-19 ギリアード サイエンシーズ， インコーポレイテッド 医薬製剤
JP2018519297A (ja) * 2015-06-30 2018-07-19 ギリアード サイエンシーズ， インコーポレイテッド テノホビルおよびエムトリシタビンを含む薬学的製剤
JP2022538449A (ja) * 2019-07-03 2022-09-02 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
JP2014500261A (ja) * 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
US11065198B2 (en) * 2016-10-24 2021-07-20 Janssen Sciences Ireland Unlimited Company Dispersible compositions
CN110958883A (zh) * 2017-06-30 2020-04-03 Viiv保健公司 组合及其用途和疗法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018519325A (ja) * 2015-06-30 2018-07-19 ギリアード サイエンシーズ， インコーポレイテッド 医薬製剤
JP2018519297A (ja) * 2015-06-30 2018-07-19 ギリアード サイエンシーズ， インコーポレイテッド テノホビルおよびエムトリシタビンを含む薬学的製剤
JP2022538449A (ja) * 2019-07-03 2022-09-02 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTIVIRAL THERAPY, vol. 23, JPN6024027045, 2018, pages 259 - 265, ISSN: 0005546393 *
DRUGS, vol. 71, JPN6024027046, 2011, pages 16 - 2131, ISSN: 0005546391 *
MEDICINE, vol. 95, no. 24, JPN6024027044, 2016, pages 3842 - 1, ISSN: 0005702104 *
THE PEDIATRIC INFECTIOUS DISEASE JOURNAL, vol. 35, no. 11, JPN6024027047, 2016, pages 1215 - 1221, ISSN: 0005546392 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538449A (ja) * 2019-07-03 2022-09-02 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー リルピビリンを用いて小児患者におけるｈｉｖを治療する方法

Also Published As

Publication number Publication date
US20210000823A1 (en) 2021-01-07
KR20220028048A (ko) 2022-03-08
CN114126655A (zh) 2022-03-01
MA56449A (fr) 2022-05-11
CN114080223A (zh) 2022-02-22
AU2020300818A1 (en) 2022-03-03
AU2020300033A1 (en) 2022-02-24
EP3993799A1 (en) 2022-05-11
BR112021026739A2 (pt) 2022-04-26
MA56453A (fr) 2022-05-11
MX2021015627A (es) 2022-04-25
PH12021553288A1 (en) 2022-08-01
CA3144307A1 (en) 2021-01-07
WO2021001568A1 (en) 2021-01-07
EP3993800A1 (en) 2022-05-11
MX2022000060A (es) 2022-04-18
US20240139186A1 (en) 2024-05-02
BR112021026916A2 (pt) 2022-05-10
KR20220028049A (ko) 2022-03-08
IL289457A (en) 2022-02-01
WO2021001508A1 (en) 2021-01-07
JP2022538449A (ja) 2022-09-02
CA3144534A1 (en) 2021-01-07
JOP20210347A1 (ar) 2023-01-30
US20220313693A1 (en) 2022-10-06

Similar Documents

Publication Publication Date Title
Robinson et al. Contraception for the HIV‐positive woman: a review of interactions between hormonal contraception and antiretroviral therapy
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
Kearney et al. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives
CN114761019A (zh) 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法
US20250302829A1 (en) Method for treating hiv with cabotegravir and rilpivirine
JP2022538338A (ja) リルピビリンを用いて小児患者におけるｈｉｖを治療する方法
EP3645003A2 (en) Combination and uses and treatments thereof
CA3144534C (en) Methods of treating hiv in pediatric patients with rilpivirine
Landman et al. COPEDOL: a two-year observational study in pretreated HIV-1-infected patients switching to a dolutegravir-based regimen
HK40069556A (en) Methods of treating hiv in pediatric patients with rilpivirine
HK40069822A (en) Methods of treating hiv in pediatric patients with rilpivirine
Bernardo-Escudero et al. Observational study of the local tolerability of injectable progesterone microspheres
RU2840867C1 (ru) Способ лечения вич каботегравиром и рилпивирином
Johnson et al. A systematic review of the use of atazanavir in women infected with HIV-1
Spagnuolo et al. Lenacapavir for the Treatment of Heavily Treatment-experienced People with Multi-class Resistant HIV.
Gaur et al. Bictegravir, Emtricitabine, and Tenofovir Alafenamide Fixed-Dose Combination for Treatment of HIV in Adolescents and Children: Week 48 Results from an Open-Label, Multicentre, Phase 2/3 Paediatric Trial
Gathe et al. Trizivir (Abacavir/Lamivudine/Zidovudine) plus Lopinavir/Ritonavir Induction Therapy Followed by Trizivir-Alone Maintenance for HIV-1-Infected Patients: A 96-Week Pilot Treatment Simplification Study

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230630

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240709

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250604

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260318

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20260325